Abstract 609P
Background
Pembrolizumab, a checkpoint inhibitor, has revolutionized the treatment of advanced melanoma by harnessing the immune system to target cancer cells. However, its use is associated with immune-related adverse events, including vitiligo and thyroid function abnormalities. This study aims to investigate the association between thyroid function abnormalities and vitiligo induced by pembrolizumab, specifically focusing on the prognosis in patients with advanced melanoma.
Methods
A retrospective survey of medical records and treatment outcomes of patients with locally advanced/metastatic melanoma receiving pembrolizumab was conducted. The study reported data on the incidence of vitiligo, thyroid function abnormalities, and their impact on prognosis. Data was collected from multiple oncology centers across Iraq. Kaplan-Meier survival curves and Cox regression were used for statistical analysis.
Results
One hundred cases with advanced melanoma were included in this study. The mean age of the samples was 55.8 ± 15.5 years old. Male to female ratio was 0.79. The Incidence of vitiligo was reported to be 27%, mainly in the survived-group (35.2%, P-value = 0.046). It took an average of 12 weeks for the development of vitiligo. The incidence of thyroid dysfunction was found to be 22%. The development of vitiligo significantly improved survival in patients with advanced melanoma (log-rank test = 0.043). On the other hand, the occurrence of thyroid dysfunction as an immune-side effect to treatment did not have an effect on the overall survival of the cohort.
Conclusions
The findings of this study suggest that there is an association between the incidence of vitiligo induced by pembrolizumab and overall survival in patients with advanced melanoma. However, no such relationship was found in regard to the development of thyroid dysfunction.
Clinical trial identification
Editorial acknowledgement
Dr. Ahmed Z. Al-Samaraee, Medical oncologist, Oncology teaching hospital, Baghdad Dr Maha S. Sahib, Clinical Pharmacist, Baghdad Dr Ayad R Alasadi, Medical oncologist, Al-Amal Hospital, Baghdad.
Legal entity responsible for the study
Oncology Teaching Hospital, Medical City Complex, Baghdad.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract
373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma
Presenter: Yen Ting Liu
Session: Poster Display
Resources:
Abstract
374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study
Presenter: Saravanan Sampoornam Pape
Session: Poster Display
Resources:
Abstract
375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand
Presenter: wanit samadee
Session: Poster Display
Resources:
Abstract
376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis
Presenter: haizhen yi
Session: Poster Display
Resources:
Abstract
377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Presenter: Parth Verma
Session: Poster Display
Resources:
Abstract
378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Presenter: zhu Liu
Session: Poster Display
Resources:
Abstract
379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
Presenter: Andhika Rachman
Session: Poster Display
Resources:
Abstract
380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract